Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Conditions: Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent; Non-squamous EGFR Wt NSCLC; Platinum Resistant Ovarian Cancer; PROC
Interventions: Drug: HWK-007
Sponsors: Whitehawk Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 4, 2026Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments